Research Analysts Set Expectations for IPA FY2028 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Stock analysts at HC Wainwright lowered their FY2028 earnings estimates for ImmunoPrecise Antibodies in a research report issued on Wednesday, December 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.13 for the year, down from their previous forecast of $0.14. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ FY2029 earnings at $0.24 EPS.

ImmunoPrecise Antibodies Price Performance

IPA stock opened at $0.40 on Thursday. The business’s fifty day moving average price is $0.47 and its 200 day moving average price is $0.72. ImmunoPrecise Antibodies has a 12-month low of $0.32 and a 12-month high of $2.60. The company has a current ratio of 0.99, a quick ratio of 0.82 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $11.54 million, a PE ratio of -0.51 and a beta of 0.06.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its earnings results on Monday, September 16th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 114.67% and a negative return on equity of 65.37%. The firm had revenue of $3.85 million during the quarter, compared to analysts’ expectations of $4.96 million.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC grew its holdings in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,558,892 shares of the company’s stock after acquiring an additional 263,451 shares during the period. Ingalls & Snyder LLC owned about 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 6.70% of the company’s stock.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.